Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Ado-trastuzumab emtansine Alectinib Antibody-drug conjugate (DMUC4064A, RG7882) Antibody-drug conjugate (RG7986) Anti-CD20/CD3 TCB (RG6026) Anti-CD20/CD3 TDB (BTCT4465A, RG7828) Anti-CD40 MAb (RG7876) Anti-CEA CD3 TCB (RG7802) Anti–FAP-IL2v FP (RG7461) Anti-OX40 MAb (MOXR0916, RG7888) Anti-TIGIT (MTIG7192A, RG6058) Atezolizumab BET inhibitor (TEN-010, RG6146) Bevacizumab Capecitabine Cergutuzumab amunaleukin (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib Codrituzumab (glypican-3 Mab) (GC33, RG7686) Emactuzumab (RG7155) Erlotinib FAP-DR5 biMAb (RG7386) HIF1 alpha LNA (RO7070179, RG6061) Idasanutlin (RG7388) Ipatasertib (GDC-0068, RG7440) LSD1 inhibitor (RG6016) Navoximod (GDC-0919, RG6078) Obinutuzumab Other Pertuzumab (RG1273) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (RG7596) Rituximab Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927/RG6047) Taselisib (GDC-0032, RG7604) Vanucizumab (RG7221) Vemurafenib Venetoclax (ABT-199/GDC-0199, RG7601) Vismodegib

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: xxx

Phase: xxx

Region: xxx

Molecule: xxx

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) BE NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) BE
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) FR NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) FR
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) NY NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Emactuzumab (RG7155) NY
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) CA NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) CA
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) DK NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) DK
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) ES NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Anti-CD40 MAb (RG7876), Vanucizumab (RG7221) ES
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
1 of 6 clinical trials
1-4 of 6 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
Results contain non-US trial information only.

Click "OK" if you wish to proceed.
CancelOK